Featured content
Manufacturing therapies that evolve: what will it take to scale living medicines?
In this interview, Christian Roghi explores the manufacturing, quality control and regulatory challenges facing living medicines; from microbiome therapeutics to phage therapies and engineered bacteria, he reveals what is needed to bring these products to market at scale.
ArticleManaging nitrosamine toxicological risk in late-stage development
Alex Gauthier at Novartis reviews practical toxicological strategies for managing late-stage nitrosamine drug substance-related impurities (NDSRIs) while maintaining patient safety and development timelines.
ReportPharma Horizons: Formulation
Discover the key technologies, risk mitigation strategies and development considerations shaping modern pharmaceutical formulation — from early-stage selection through to commercial-scale manufacturing.
ArticleEuropean Pharmaceutical Review Issue 2 2026
EPR Issue 2 includes articles on manufacturing, drug formulation, microbiology, downstream bioprocessing, and more.
News
NewsUK industry clinical trial recruitment falls for fifth consecutive year
News plus: The number of patients recruited to industry-sponsored clinical trials in the UK fell by 31 percent between 2022/23 and 2025/26, despite improvements in the speed of trial setup, according to the ABPI.
NewsMerck to divest CDMO business across five US sites to Lonza
Merck has signed a definitive agreement to sell its CDMO business to Lonza for a mid-triple-digit million-euro sum, with the transaction expected to complete in mid-2027.
News​FDA finalises cell and gene therapy potency guidance
The FDA has issued final guidance outlining a science- and risk-based approach to potency assurance for CGT products, replacing its previous 2011 recommendations and setting out expectations across the product lifecycle.
NewsEnteroBiotix appoints former GSK Chief Medical Officer to Board
EnteroBiotix has appointed Dr Murray Stewart, former Chief Medical Officer at GSK, to its Board of Directors as the company advances its Phase 2b programme for irritable bowel syndrome with constipation (IBS-C).
From our partners
Large-scale AAV manufacturing for non-rare diseases
As AAV therapies move beyond rare disease indications, manufacturing scalability becomes critical. Learn how an integrated approach to process development can help reduce risk, improve yields, and prepare for commercial success.
Pharma Horizons: Formulation
Discover the key technologies, risk mitigation strategies and development considerations shaping modern pharmaceutical formulation — from early-stage selection through to commercial-scale manufacturing.
Opinion and interviews
Manufacturing therapies that evolve: what will it take to scale living medicines?
In this interview, Christian Roghi explores the manufacturing, quality control and regulatory challenges facing living medicines; from microbiome therapeutics to phage therapies and engineered bacteria, he reveals what is needed to bring these products to market at scale.
Manufacturing the route: oral and injectable drug delivery
Jennifer Gattari of Pfizer CentreOne discusses how patient needs, evolving delivery formats and emerging manufacturing trends are shaping the pharmaceutical industry, from oral solid dose products to sterile injectables.
- Previous
- Next
Join now
Unlock exclusive industry insights
- Bookmark articles and resources to access anytime
- Enjoy free access to industry leading resources, webinars and insights
- Stay informed with the latest news and breakthroughs in drug discovery
- Receive updates and recommendations tailored to your research interests
Upcoming Webinars
Webinar
The impact of negative control stability on recombinant endotoxin testing
Discover how to achieve stable negative control (NC) performance for sensitive and precise recombinant endotoxin testing.
Webinar
Building quality and consistency into accelerated cell and gene therapy development
How can cell and gene therapy manufacturers move programmes forward faster without compromising quality, scalability or regulatory readiness?
The impact of negative control stability on recombinant endotoxin testing
Building quality and consistency into accelerated cell and gene therapy development
On-demand Webinars
- Previous
- Next
